News

Smart for Life Announces Completion of Audit for Pending Acquisition

Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net IncomeMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE)…

2 years ago

Stryker to announce financial results for its fourth quarter and full year 2023

Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter…

2 years ago

First ReWalk Personal Exoskeleton Claim Paid by Medicare

ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injuryMARLBOROUGH, Mass. and…

2 years ago

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests…

2 years ago

Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for…

2 years ago

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel…

2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…

2 years ago

Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x…

2 years ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on…

2 years ago

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue

Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix GoSAN FRANCISCO, Jan. 05, 2024 (GLOBE…

2 years ago